A cluster of phosphorylation sites in LRRK2 (leucine-rich repeat kinase 2), including Ser 910 , Ser 935 , Ser 955 and Ser 973 , is important for PD (Parkinson's disease) pathogenesis as several PD-linked LRRK2 mutants are dephosphorylated at these sites. LRRK2 is also dephosphorylated in cells after pharmacological inhibition of its kinase activity, which is currently proposed as a strategy for disease-modifying PD therapy. Despite this importance of LRRK2 dephosphorylation in mutant LRRK2 pathological mechanism(s) and in LRRK2 s response to inhibition, the mechanism by which this occurs is unknown. Therefore we aimed to identify the phosphatase for LRRK2. Using a panel of recombinant phosphatases, we found that PP1 (protein phosphatase 1) efficiently dephosphorylates LRRK2 in vitro. PP1 activity on LRRK2 dephosphorylation was confirmed in cells using PP1 inhibition to reverse LRRK2 dephosphorylation induced by the potent LRRK2 kinase inhibitor LRRK2-IN1 as well as in R1441G mutant LRRK2. We also found that PP1 and LRRK2 can form a complex in cells. Furthermore, we observed that PP1 inhibition modulates LRRK2 s cellular phenotype by reducing skein-like LRRK2-positive structures associated with dephosphorylation. In conclusion, the present study reveals PP1 as the physiological LRRK2 phosphatase, responsible for LRRK2 dephosphorylation observed in PD mutant LRRK2 and after LRRK2 kinase inhibition.
INTRODUCTION
Mutations in the LRRK2 (leucine-rich repeat kinase 2) gene are a common cause of inherited forms of PD (Parkinson's disease) [1, 2] . Moreover, genome-wide association studies have identified LRRK2 as a risk factor for sporadic PD [3] [4] [5] [6] . LRRK2 encodes a large multi-domain protein comprising, among others, domains with GTPase and kinase activity. The essential catalytic core encompasses the GTPase domain, termed ROC (Ras of complex proteins), which is linked to the kinase domain via the COR (C-terminal of ROC) domain. The catalytic segment of LRRK2 is flanked at its C-terminus by a WD40 domain and at the N-terminus by armadillo and ankyrin repeats and the namesake leucine-rich repeat domain [7] (Supplementary Figure  S1 at http://www.biochemj.org/bj/456/bj4560119add.htm). Of the many LRRK2 substitutions described, the majority of those that are proven to be pathogenic are concentrated in the catalytic core: N1437H, R1441C/G/H and Y1699C in the ROC-COR bidomain and G2019S and I2020T in the kinase domain [8] (Supplementary Figure S1) . The most common mutation in patients, G2019S, is located in the kinase domain and has consistently been shown to increase kinase activity 2-3-fold [9] , suggesting that targeting kinase activity might be a therapeutic strategy [10] . The other pathogenic substitutions, R1441C/G/H, Y1699C and I2020T, have more modest effects on kinase activity [9, [11] [12] [13] .
The LRRK2 protein is phosphorylated at multiple sites, but the regulation of its phosphorylation is not fully understood [14] [15] [16] [17] [18] . LRRK2 displays two distinct clusters of phosphosites, one set of autophosphorylation sites with low or no basal phosphorylation levels in cells and a second set of serine residues with high basal phosphorylation levels located between the ankyrin and leucine-rich repeat domains (Supplementary Figure  S1 ) [19] . Evidence suggests that these sites, including Ser 910 , Ser 935 , Ser 955 and Ser 973 , are phosphorylated by kinases other than LRRK2 itself ( [12, 16, 17, 19, 20] and Supplementary Figure  S2 at http://www.biochemj.org/bj/456/bj4560119add.htm). Some nominated kinases are PKA (protein kinase A) or the IKK (inhibitor of κB kinase) family which phosphorylate LRRK2 when activated [16, 21] , although administration of the PKA inhibitor H89 does not significantly block total or Ser 935 phosphorylation [22, 23] . Antibodies against the Ser 910 /Ser 935 /Ser 955 / Ser 973 sites label LRRK2 extracted from cells or from the brain, showing that these are physiologically relevant modifications of the protein in vivo [24] .
Changes in the cellular LRRK2 phosphorylation status are linked to the pathogenesis of LRRK2-related PD as disease-associated mutations R1441G/C/H, Y1699C, I2020T and G2385R display reduced phosphorylation at these sites compared with WT (wild-type) LRRK2 [16, 17, 20] . Cellular LRRK2 phosphorylation governs a number of LRRK2-mediated processes, including regulation of the cellular LRRK2 complex and subcellular localization. Indeed, decreased cellular phosphorylation correlates with decrements in phospho-dependent 14-3-3 binding and consequent subcellular relocalization of LRRK2 [17] . PD mutations that induce cytoplasmic accumulation of LRRK2 can relocalize to both filamentous and large inclusions in different cell types [17, [25] [26] [27] .
Interestingly, many laboratories have observed that acute inhibition of LRRK2 kinase activity leads to dephosphorylation of LRRK2, loss of 14-3-3 binding [15, 16, 20, 24] as well as subcellular relocalization to skein-like structures [14, 15, 24] . Typically, these structures are filamentous and co-localize with microtubules [15] . This is a crucial observation, as this potential therapeutic avenue for PD induces cellular phenotypes (decreased phosphorylation, loss of 14-3-3 binding and relocalization) that are similar to pathogenic PD mutations in LRRK2. The nexus of these events is the dephosphorylation of LRRK2.
Taken together, the available data show that phosphorylation of LRRK2 is a highly regulated physiological event that is relevant to the effects of PD-related mutations and represents a potential pharmacodynamic marker for the effects of kinase inhibitors [22] . However, little is known about the regulation of LRRK2 phosphorylation and the data indicate that dephosphorylation is a unifying theme of PD mutations and LRRK2 kinase inhibition. We therefore set out to identify the major phosphatase(s) responsible for regulating LRRK2 phosphorylation. Using a combination of in vitro, pharmacological and molecular approaches, we identified PP1 (protein phosphatase 1) as a key LRRK2 phosphatase in physiological and pathological conditions. These results provide a mechanistic explanation for the altered phosphorylation of pathogenic LRRK2 variants and following cellular treatment with the potent LRRK2 kinase inhibitor LRRK2-IN1 [24] .
MATERIALS AND METHODS

Cell culture and transfection
HEK (human embryonic kidney)-293T cells, NIH 3T3 cells and SH-SY5Y cells were maintained in DMEM (Dulbecco's modified Eagle's medium) (Gibco-Life Technologies) supplemented with 8 % or 15 % heat-inactivated FBS (Harlan Sera-Lab) and 50 μg/ml gentamycin at 37
• C in a humidified atmosphere containing 5 % CO 2 . A549 cells were maintained in RPMI medium with L-glutamine supplemented with 10 % FBS, and 0.1 mM MEM (modified essential medium) Non-Essential Amino Acids solution. Overexpression of LRRK2 in HEK-293T and SH-SY5Y cells was obtained by transduction with a lentiviral vector encoding 3×FLAG-LRRK2 or eGFP-LRRK2. Lentiviral vectors encoding human 3×FLAG-LRRK2 and eGFP-LRRK2 under control of the CMV (cytomegalovirus) promoter were prepared as described previously [28] . For transduction in cell culture, 50 000 HEK-293T or SH-SY5Y cells were plated in a 24-well plate. The next day, vector was applied to the cells for 2 days. This procedure was repeated twice with the same cells to obtain triple transduced cells. These cells were then expanded for use in experiments. HEK-293 T-REx cell lines were cultured in DMEM supplemented with 10 % FBS and 2 mM glutamine, 1× antimycotic/antibiotic, 15 μg/ml blasticidin and 100 μg/ml hygromycin. T-REx cultures were induced to express the indicated protein by inclusion of 1 μg/ml doxycycline in the culture medium for 24 h. Transfections were performed 24 h after seeding for 48 h with linear polyethylenimine (Polysciences Europe) according to the manufacturer's protocol. For co-immunoprecipitation, T-REx HEK-293 cells were transfected using polyethylenimine [29] . All cultures were mycoplasma-free.
Pharmacological treatment of cells
Cells grown until 50-100 % confluency were treated with the indicated compounds, dissolved in pre-warmed culture medium to the final treatment concentration, for the time indicated and with DMSO treatment as a negative control. Except where indicated, cells were rinsed twice in PBS and lysed in lysis buffer [20 mM Tris/HCl, pH 7.5, 150 mM NaCl, 1 mM EDTA, 1 % Triton X-100, 10 % (v/v) glycerol, protease inhibitor cocktail and phosphatase inhibitor cocktail (Roche)] or as described in [14] . Cell lysates were cleared by centrifugation at 15 000 g for 10 min. Membranes were processed as described in the Supplementary Materials and methods section (at http://www. biochemj.org/bj/456/bj4560119add.htm).
Metabolic labelling
Metabolic labelling was performed essentially as described in [30] . Briefly, cells expressing LRRK2 were rinsed twice in DMEM without phosphates and then labelled with 5 μCi/cm 2 [
32 P]P i (PerkinElmer) at 37
• C. Following 4-8 h labelling, cells were lysed and LRRK2 was immunoprecipitated using FLAG-M2-agarose beads (Sigma). Immunoprecipitated protein was resolved on Nupage 3-8 % tris-acetate SDS/PAGE gels (Invitrogen) and immunoblotted. Membranes were stained with Ponceau S (Sigma) to visualize proteins. Membranes were processed as described in the Supplementary Materials and methods section.
Statistics
Unless otherwise indicated, the Figures shown are representative of at least three independent experiments. Phosphorylation levels were normalized for expression levels and experimental test conditions were normalized to control conditions. Statistical analysis was performed using one-way ANOVA or one-sample t test comparing test values with the hypothetical value of 1 with Bonferroni correction for multiple comparisons as appropriate. For counting of skein-like structures in cells, analysis was performed with Fisher's exact test on the proportion of cells with skein-like inclusions out of all transfection-positive cells. Statistical significance was set at P < 0.05.
RESULTS
PP1α efficiently dephosphorylates LRRK2 in vitro
We first identified phosphatases able to dephosphorylate cellular LRRK2 phosphorylation sites in vitro from a panel of catalytic subunits of common serine/threonine phosphatases. To visualize total phosphorylation levels, LRRK2 was metabolically labelled with 32 P in HEK-293T cells overexpressing 3×FLAG-LRRK2, affinity purified and incubated with phosphatases at a limiting concentration (12.5 units/ml, see the Supplementary Materials and methods section). Alkaline phosphatase (250 units/ml) was included as a positive control [17] . All phosphatases were active under these experimental conditions against the test substrates phosphorylated MBP (myelin basic protein) or pNPP (pnitrophenyl phosphate) (Supplementary Figure S3 at http://www. biochemj.org/bj/456/bj4560119add.htm). We found that PP1α (HGNC symbol PPP1CA) was able to dephosphorylate LRRK2 to the same extent as the positive control. Using antibodies and Ser 973 measured using phosphosite-specific anti-LRRK2 antibodies. Total LRRK2 levels were detected using both Ponceau S and immunoblotting. The graphs show the quantification of incorporated 32 P in LRRK2 after in vitro dephosphorylation normalized to total LRRK2 levels using immunoblotting of three independent experiments, + − S.E.M. Blots show representative results. Statistical significance was assessed by single sample t tests combined with Bonferroni correction for multiple testing. **P < 0.01. Ap, alkaline phosphatase.
against pSer 910 , pSer 935 , pSer 955 and pSer 973 LRRK2, we found that all individual sites were efficiently dephosphorylated by PP1α. Partial dephosphorylation was observed after treatment with PP2A1 (HGNC symbol PPP2CA) as well as with PPλ (Figure 1 ), although this did not reach statistical significance. These results identify PP1α as a candidate phosphatase for the constitutive phosphorylation sites of LRRK2.
LRRK2 interacts with PP1α
We next considered whether different PP1 isoforms were LRRK2 phosphatases in vivo. First, we examined localization in cells and found that LRRK2 strongly co-localized with PP1α and PP1β in the cytoplasm (Figure 2A ). PP1γ was primarily localized to the nucleus, although LRRK2 co-localized with the fraction of PP1γ present in the cytoplasm (Figure 2A ). Secondly, we examined whether PP1 isoforms physically bound LRRK2. We transiently expressed FLAG-tagged PP1 isoforms or PP2Aα in HEK-293 T-REx cells expressing GFP or GFP-LRRK2. We found that PP1α formed a non-ionic detergent-stable complex with LRRK2, whereas interaction of LRRK2 with PP1β, PP1γ or PP2Aα was not detected under the same conditions ( Figure 2B ). We also observed that the LRRK2-PP1α interaction was enhanced after LRRK2-IN1 treatment and abolished after treatment with calyculin A (an inhibitor of PP1 and PP2A). The immunoblot for pSer 935 and the 14-3-3 overlay assay were used to confirm the induced dephosphorylation of LRRK2 after inhibition [17, 20] ( Figure 2B ).
Thirdly, we verified spatial proximity of these molecules in situ using the PLA (proximity ligation assay) [31] . We performed in situ PLA on cells co-expressing FLAG-tagged PP1α and GFP-LRRK2 and quantified the number of individual ligation amplification signals per cell ( Figure 2C ). Control amplifications with only single antibody (anti-GFP or anti-FLAG alone) staining, where both antigens are present yielded no PLA signals. Additionally, no PLA signals were observed when both antibody probes were applied to vector-transfected cells, where tagged PP1 is not present but LRRK2 is expressed. We observed specific and significant PLA signals for PP1 and LRRK2 when antibodies against both epitope tags are used and both GFP-LRRK2 and FLAG-PP1 are expressed, verifying in vivo interaction of these molecules.
The enhanced interaction of PP1α with LRRK2 after acute inhibition prompted us to test whether there is a similar recruitment of PP1 to mutants of LRRK2 that are dephosphorylated. We compared the interaction of FLAG-PP1α with GFP variants of LRRK2 expressed in inducible HEK-293 TREx cells and found enhanced binding for mutants with reduced basal phosphorylation, such as N1437H, R1441G and Y1699C, as well as for the combined S910/935/955/973A ( Figure 2D ). As a positive control, we tested for HSP90 (heat-shock protein 90) co-immunoprecipitation and observed interaction with LRRK2 that was enhanced with LRRK2 aggregation-prone mutations as seen previously [17, 20, 32] .
We confirmed the LRRK2-PP1 interaction for endogenous LRRK2 and PP1α in A549 cells ( Figure 2E ). Furthermore, we could show an LRRK2-IN1-induced increase in the endogenous PP1α-LRRK2 interaction ( Figure 2E ).
Pharmacological inhibition of PP1 prevents LRRK2 dephosphorylation
We next tested whether inhibition of PP1 with small molecules would prevent dephosphorylation of LRRK2. We first treated HEK-293T cells, stably overexpressing LRRK2, with calyculin A or okadaic acid (a PP2A-selective inhibitor at the used concentration) [33] and found that neither compound affected overall LRRK2 phosphorylation under basal conditions ( Figure 3A ). Next, we tested phosphatase inhibition in conditions of induced dephosphorylation after inhibition of LRRK2 kinase activity and found that calyculin A prevents the dephosphorylation effect of LRRK2-IN1, whereas okadaic acid did not ( Figure 3A ). These results suggest that PP1 is an authentic phosphatase for LRRK2, and its effect is strongest under conditions where LRRK2 dephosphorylation is induced.
We confirmed these results using phospho-LRRK2-specific antibodies. First, T-REx HEK-293 cells with WT LRRK2 overexpression were treated with calyculin A or okadaic acid at different concentrations, in the presence or absence of LRRK2-IN1. Consistent with the metabolic labelling data, LRRK2-IN1-induced LRRK2 dephosphorylation could be prevented by calyculin A, but not by okadaic acid ( Figure 3B ). Interestingly, the low basal phosphorylation level of the LRRK2 R1441G mutant was restored to WT levels by treatment with calyculin A, but not with okadaic acid ( Figure 3B ). LRRK2-IN1-induced LRRK2 dephosphorylation was counteracted by calyculin A treatment, even at relatively low concentrations of 5 or 20 nM, but not by okadaic acid at concentrations up to 100 nM in a second cell type, stable SH-SY5Y cell lines ( Figure 3C ). We also employed a recently developed homogeneous and ratiometric assay to detect LRRK2 modification at Ser 935 [22] in the absence or presence of LRRK2-IN1 (1 μM) across a
Figure 2 PP1α interacts with LRRK2
(A) HEK-293T cells with stable eGFP-LRRK2 expression were transfected with 3×FLAG-tagged PP1α, PP1β or PP1γ . Cells were stained with DAPI (blue, left-hand panels), and proteins were detected by immunofluorescence using FLAG for PP1 isoforms (red, second panels) and eGFP for LRRK2 (green, third panels). We next asked whether the regulation of LRRK2 phosphorylation is also similar for endogenous protein. Similar to our experiments on overexpressed LRRK2, treatment with calyculin A could also overcome endogenous LRRK2 dephosphorylation induced by LRRK2-IN1 in NIH 3T3 cells ( Figure 4A ) and in primary neurons ( Figure 4B ). In addition, calyculin A increased endogenous LRRK2 phosphorylation levels in primary neurons ( Figure 4B ). Okadaic acid treatment also showed a trend to increased pSer 935 levels, suggesting that PP2A may also contribute in neurons, although this was to a much lower extent than calyculin A. These results show that, in all cell types tested, including in neurons, PP1 is the major phosphatase for LRRK2.
Molecular inhibition of PP1 counteracts LRRK2 dephosphorylation induced by kinase inhibition
Since no specific pharmacological PP1 inhibitors are available, we wanted to confirm our data using highly specific and potent protein inhibitors of PP1, namely I2 (inhibitor-2, HGNC symbol PPP1R2) [34] or the central domain (residues 143-224) of NIPP1 (nuclear inhibitor of PP1, HGNC symbol PPP1R8) [35] . We overexpressed these protein inhibitors of PP1 in HEK-293T cells stably overexpressing LRRK2 (Supplementary Figure  S4 at http://www.biochemj.org/bj/456/bj4560119add.htm) and investigated the effects on the phosphorylation level of LRRK2. Overexpression of I2 or NIPP1 143-224 had no effect on basal LRRK2 phosphorylation level compared with an eGFP control. However, overexpression of NIPP1 143-224 prevented LRRK2-IN1-induced LRRK2 dephosphorylation, consistent with the effects of pharmacological PP1 inhibition using calyculin A ( Figure 5 ).
Pharmacological inhibition of PP1 prevents formation of LRRK2 skein-like structures
Dephosphorylation of LRRK2 induced by kinase inhibition [14, 15, 24] or by some pathogenic mutations [17, [25] [26] [27] Figure 6C) . A similar decrease in cells with skeinlike inclusions was observed for the pathogenic LRRK2 mutants R1441C, Y1699C and G2019S after treatment with both drugs. However, we did not observe a significant reduction in the number of cells with skein-like structures for S910A/S935A, R1441G and I2020T mutants, possibly related to a strong binding of these variants to PP1α (results not shown).
The decreased percentage of cells with skein-like structures after treatment with only 5 nM of calyculin A, both in conditions of LRRK2-IN1 treatment and in mutations, confirms the link between LRRK2 dephosphorylation and the formation of skeinlike inclusions and point to a role for PP1 in this process.
DISCUSSION
Similar to many kinases, LRRK2 is also a phosphoprotein and a particular cluster of phosphosites in the interdomain region between the ankyrin repeat and leucine-rich repeat domains, including sites Ser 910 /Ser 935 /Ser 955 /Ser 973 , is subject to regulation. The identification of regulators of LRRK2 cellular phosphorylation at these sites may provide an insight into the molecular basis of PD as well as into the consequences of kinase inhibition. Although studies researching kinases upstream of these sites have begun to be reported [16, 21, 23] , there are no reports of phosphatases that can affect cellular LRRK2 phosphorylation. In the present study we employed a combination of in vitro,
Figure 5 Molecular inhibition of PP1 prevents LRRK2 dephosphorylation induced by LRRK2-IN1
HEK-293T cells with stable eGFP-LRRK2 overexpression were transfected with expression constructs for the PP1 molecular inhibitors I2 or NIPP1 143-224 , or with a control construct encoding eGFP. Cells were treated with 1 μM LRRK2-IN1 or DMSO as a control for 30 min followed by cell lysis and immunoblotting with the different phosphorylation-site-specific anti-LRRK2 antibodies. Representative blots of three independent experiments are shown. Quantification of the blots are represented as a histogram. For quantification, the ratio of phosphorylation over total LRRK2 signal was normalized to control condition and are means + − S.E.M. The blots show representative results. Statistical significance was assessed by column statistics combined with Bonferroni correction for multiple testing. *P < 0.05, **P < 0.01. . Statistical significances were tested using a Fisher's exact test. *P < 0.05, **P < 0.01, ***P < 0.001. ns, not significant. pharmacological and molecular cell biology approaches to identify phosphatases regulating LRRK2 phosphorylation at Ser 910 /Ser 935 /Ser 955 /Ser 973 . First, using a panel of recombinant serine-threonine phosphatases, we show that only PP1 efficiently dephosphorylated LRRK2 in vitro at the four different cellular phosphorylation sites tested. Secondly, pharmacological inhibition of PP1, but not of PP2A, prevents LRRK2-IN1-induced dephosphorylation in five different cell types, including in HEK-293T, SH-SY5Y and U2OS cell lines as well as on endogenous LRRK2 in NIH 3T3 cells and mouse primary neuron cultures. It should be noted that a trend towards increased phosphorylation was observed after PP2A inhibition with okadaic acid in primary neurons, suggesting that PP2A may play an auxiliary role in dephosphorylation of LRRK2 under specific conditions or cell types. Inhibition of PP1 also restores the reduced phosphorylation level of the R1441G disease mutant to WT levels. Finally, the functional relevance of PP1-mediated LRRK2 phosphoregulation was confirmed by the observation that PP1 inhibition reduces the formation of skeinlike structures, which have previously been shown to be associated with dephosphorylated LRRK2 [14, 15, 17, [24] [25] [26] [27] , both for mutant forms of LRRK2 as well as after LRRK2 kinase inhibition. From these results, we conclude that PP1 is a regulator of the LRRK2 phosphorylation cycle (Figure 7) .
The results of the present study suggest that LRRK2 dephosphorylation involves the enhanced access of PP1 to LRRK2 phosphosites. The PP1α interaction with LRRK2 is weak under basal conditions, consistent with rapid binding kinetics for phosphatases. However, we found that some pathogenic mutant forms of LRRK2, such as R1441G or Y1699C, had increased interaction with PP1α. These data are consistent with the previous observation that most LRRK2 PD mutations have decreased phosphorylation at Ser 910 /Ser 935 [14, 16, 17] . Our data also show that transient inhibition of kinase activity of LRRK2 by small molecules leads to enhanced interaction between PP1α and LRRK2.
Several considerations point to conformational changes in LRRK2 to enable PP1 action as a regulatory mechanism of LRRK2 dephosphorylation. For example, pathogenic mutants with reduced phosphorylation levels such as R1441G and Y1699C display a weakened dimerization which could be explained by an enhanced intramolecular ROC-COR interaction [36, 37] . Therefore enhanced PP1 recruitment/activity appears to correlate to altered properties of the LRRK2 catalytic core either via reduced ROC-COR dimerization or through structural or compound-induced changes in the ATP-binding pocket of the kinase domain. Resolving the crystal structure of the entire LRRK2 molecule may be required to further test these hypotheses.
Phosphorylation levels of cellular proteins are determined by the net effect of phosphorylation by kinases and dephosphorylation by phosphatases. To date, PKA [16, 23] and IκB (inhibitor of nuclear factor κB) kinases [21] have been suggested to be responsible for the cellular phosphorylation of LRRK2. However, the rapid dephosphorylation induced by LRRK2-IN1 (>80 % dephosphorylation after 90 min [21, 24] ) and the relatively long half-life of LRRK2 in cells [38, 39] , suggests that enhanced dephosphorylation rather than decreased phosphorylation of LRRK2 by kinases could be the primary mechanism of LRRK2 dephosphorylation. This conclusion is also in line with our finding that PP1 activity is necessary for LRRK2 to become dephosphorylated. Cellular PP1 activity is provided by a holoenzyme, which consists of a catalytic subunit bound to one or two regulatory subunits that provide substrate specificity [40, 41] . There are three different isoforms of the PP1 catalytic subunit, namely PP1α, PP1β and PP1γ , which have identical catalytic properties and are all sensitive to the inhibitors used in the present study. As our results show that PP1α preferentially interacts with LRRK2, this suggests that PP1α is the primary PP1 isoform active on LRRK2. All three PP1 isoforms are widely expressed with high abundance in the brain where they have been shown to play a role in different neuronal processes such as synaptic plasticity and memory [42, 43] . Intriguingly, both LRRK2 [44, 45] and PP1α [46] are specifically enriched in the striatum.
The present study points to new possibilities in targeting LRRK2 function. PP1 can be targeted in a highly specific manner to its substrate through its interaction with regulatory subunits [41] . This unique complex, including the PP1 substrate, PP1 and PP1 regulatory subunits could be disrupted with specific proteinprotein interaction inhibitors of the interaction between the PP1 catalytic subunit (PP1α) and its regulatory subunits or its substrate [47] . Further research is needed to identify the specific regulatory components of the LRRK2-specific PP1 holoenzyme in order to test this approach.
In summary, we provide the first report confirming a phosphatase, PP1, as a physiological regulator of LRRK2 cellular phosphorylation in cell lines and in neurons. Mechanistically, we find that dephosphorylation is perhaps mediated by enhanced accessibility of PP1 to the LRRK2 complex, thereby explaining why LRRK2 is dephosphorylated following kinase inhibition or in disease mutants. By revealing a major regulator of LRRK2 phosphorylation in cells, the present study provides new insight into the regulation of LRRK2 physiological and pathological functions and points to the molecular consequences of a much discussed potential therapy for PD, namely LRRK2 kinase inhibition. 
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MATERIALS AND METHODS
Constructs, antibodies and reagents
PP1α and PP1γ were cloned from PlasmidID clones HsCD00004106 and HsCD00005169. PP1β was cloned from PlasmidID clone HsCD00000467, the sequence has an L51P mutation, and was corrected to WT using the GeneArt Site-Directed Mutagenesis System (Invitrogen). PP2Aα was cloned from Addgene plasmid 10689 [1] . All of the constructs were inserted into the pcDNA5-FRT/TO backbone with an Nterminal FLAG tag. Constructs of truncated NIPP1 (NIPP1 143-224 , residues 143-224) and I2 with N-terminal tags of eGFP and CFP respectively are described in [2] . 3 × FLAG-LRRK2 constructs are described by Daniëls et al. [3] . eGFP-tagged constructs of LRRK2 were generated by cleaving out the 3 × FLAG tag and ligating an eGFP sequence derived from the pEGFP-C1 plasmid. N-terminal eGFP-tagged LRRK2 used for the T-Rex cell line was cloned into the pcDNA5-FRT/TO backbone for generation of T-REx cell lines. All constructs were confirmed by restriction digest analysis and sequencing. Recombinant protein phosphatases were purchased from Calbiochem (EMD Millipore Chemicals). LRRK2 was detected with the anti-LRRK2 antibody N138/6 (Neuromab) or monoclonal rabbit anti-LRRK2 antibody MJFF-2 (clone C41-2, Epitomics). The immunoprecipitation of endogenous LRRK2 was performed with a monoclonal rabbit antibody directed against LRRK2 residues 100-500 (5097-5091; Epitomics). Sheep anti-LRRK2 pSer 910 (S357C) was used as described in [4] and monoclonal rabbit anti-pSer 910 and pSer 935 co-developed by the Michael J. Fox Foundation, Epitomics and University of Dundee were described in [5] , polyclonal rabbit anti-LRRK2 pSer 935 , pSer 955 and pSer 973 are described in [6] . FLAG M2 antibody was purchased from Sigma-Aldrich, eGFP antibody was produced in-house [7] , from Roche (clones 7.1 and 13.1) or rabbit monoclonal anti-GFP from LifeTechnologies was used for PLAs. Mouse monoclonal anti-pan-PP1 antibody was described previously in [8] and anti-PP1α antibody was from Santa Cruz Biotechnology, Life Technologies (clone 10C6-10C3) or Cell Signaling Technologies. Anti-β-tubulin antibody was purchased from Sigma. Rat anti-pan-tubulin antibody was purchased from Santa Cruz Biotechnology. LiCOR DyeLight labelled 14-13-3 protein (recombinant His-tagged BMH1&2, a gift from Professor Dario Alessi, MRC Protein Phosphorylation and Ubiquitylation Unit, Department of Biochemistry, University of Dundee, Dundee DD1 5EH, U.K.) was prepared according to the manufacturer's instructions and used to detect 14-3-3 binding as described previously [6, 9] , calyculin A was obtained from Enzo Life Sciences, okadaic acid was purchased from Merck and LRRK2-IN1 was used as described in [10] . GFP-Trap Agarose was purchased from Chromotek.
Isolation and culture of primary neurons
Primary cortical neurons were prepared from newborn (P 0 ; postnatal day zero) pups (C57BL/6J). Neuronal cells were dissociated by papain (Worthington), plated on to 6-well plates precoated with poly-D-lysine (BD Biosciences) at a density of 2.5 × 10 6 cells/well in Basal Medium Eagle (Sigma-Aldrich) supplemented with B27, N2, glutaMAX-I, penicillin/streptomycin (Invitrogen) and 0.45 % glucose (Sigma-Aldrich). The medium was replaced by half every 2 days. Cytosine arabinoside (3 μM; Sigma-Aldrich) was added for the first 3 days to inhibit glial cell proliferation. At 14 DIV (days in vitro), neurons were treated for 30 min with 20 or 100 nM calyculin A, 100 nM okadaic acid, 1 μM LRRK2-IN1, 20 nM calyculin A and 1 μM LRRK2-IN1 or DMSO alone. Cells were collected and spun down at 16 000 g for 10 min. The pellet was lysed in 30 μl of buffer containing 10 mM Tris/HCl, 2 % SDS, protease inhibitors cocktail (Roche), and HALT phosphatase inhibitor cocktail (Thermo Scientific), sonicated and subjected to immunoblot analysis. All mouse work followed the guidelines approved by the Institutional Animal Care and Use Committees of the National Institute of Child Health and Human Development.
In vitro dephosphorylation
For the dephosphorylation of radioactively labelled LRRK2, HEK-293T cells expressing 3 × FLAG-LRRK2 were grown to confluence in 10-cm-diameter petri dishes then metabolically labelled as described above. Following labelling, cells were lysed and 3 × FLAG-LRRK2 was purified as described above. FLAG-M2 beads holding the purified 3 × FLAG-LRRK2 were rinsed in dephosphorylation buffer (20 mM Tris, pH 7.5, 10 mM MgCl 2 , 2 mM DTT and 0.02 % Triton) and protein was eluted using 3 × FLAG peptide (0.1 mg/ml, Sigma). Protein (approximately 10 μg/ml) was incubated with a panel of recombinant phosphatase catalytic subunits (PP1α, PP2A 1 , PP2A 2 , PP2B, PP2Cα and PPλ, all from Calbiochem, Merck Millipore) at the limiting concentration of 12.5 units per ml, as well as an alkaline phosphatase control (250 units/ml) (Fermentas, Thermo Scientific) for 30 min at 30
• C. Reactions were stopped by the addition of SDS loading dye. Samples were resolved on Nupage 3-8 % Tris-acetate gels. Incorporated 32 P was detected by autoradiography using a Storm 840 phosphorescence scanner (GE Healthcare). The same membranes were stained with Ponceau S (Sigma) to correct for protein loading and probed with the monoclonal rabbit anti-LRRK2 antibody MJFF-2 to confirm the presence of LRRK2.
Co-immunoprecipitation (co-IP)
Per 10-cm-diameter dish of T-REx HEK-293 cells overexpressing GFP-LRRK2, cells were washed once with PBS and lysed in situ with 500 μl of lysis buffer (50 mM Tris/HCl, pH 7.4, 1 mM EGTA, 1 mM EDTA, 0.27 M sucrose, 1 mM benzamidine and 1 mM PMSF and was supplemented with 1 % Nonidet P40) on ice, then centrifuged at 15 000 g at 4
• C for 15 min. Protein concentrations were determined using the Bradford method with BSA as the standard. Cell lysates were subjected to immunoprecipitation with GFP-Trap agarose beads at 5 μl beads per 500 μl lysate for 1 h at 4
• C. Beads were washed twice with lysis buffer supplemented with 300 mM NaCl, then twice with buffer A (50 mM Tris/HCl, pH 7.4, 50 mM NaCl, 0.1 mM EGTA and 0.27 M sucrose). Immune complexes were incubated in NuPAGE LDS (lithium dodecyl sulphate) sample buffer at 70
• C for 10 min, then boiled for 5 min.
Confluent dishes of A549 cells were treated with 2 μM LRRK2-IN1 for 90 min, or 20 nM calyculin A for 30 min. Then cell lysates were prepared and subjected to immunoprecipitation as described above for GFP-Trap with 6 μg/10-cm-diameter dish of anti-LRRK2 100-500 (Epitomics) or rabbit IgG (Bethyl) for 2 h at 4
• C.
Gel electrophoresis and immunoblotting
The protein content of cell lysates was determined using the BCA protein determination assay (Pierce Biotechnology) or the Bradford method. Cell lysates were boiled and resolved by electrophoresis on a NuPage 3-8 % tris-acetate gradient gel, 4-12 % Bis-Tris gradient gel or 12.5 % SDS gel. Separated proteins were transferred on to a PVDF membrane (Bio-Rad Laboratories) or Protran Nitrocellulose membrane (Whatman, GE Healthcare) and non-specific binding sites were blocked for 30 min in PBST (PBS supplemented with 0.1 % Triton X-100) or TBST (Trisbuffered saline with 0.1 % Tween 20) and 5 % (w/v) non-fat dried skimmed milk powder or 5 % BSA. After overnight incubation at 4
• C with the appropriate antibodies, blots were washed three times with PBST. After incubation with the appropriate horseradish peroxidase-conjugated secondary antibody (Dako) for 1 h, blots were washed again as mentioned before. Bands were visualized using ECL (GE Healthcare) or LI-COR dual probes (Lincoln). To normalize the signal of phospho-specific antibodies to LRRK2 expression levels, blots were stripped after detection of the phospho-specific signal and reprobed with anti-LRRK2 antibody. To strip antibodies from a blot, the blot was incubated with methanol for 30 s, followed by two wash steps of 5 min with distilled water and two wash steps with PBST. Next, the blot was incubated with stripping buffer (62.5 mM Tris/HCl, pH 6.8, 2 % SDS and 100 mM 2-mercaptoethanol) for 30 min at 70
• C, followed by two 10 min wash steps with PBST. Immunodetection on stripped blots was performed as described above. Densitometric analysis of the bands on the blot autoradiograms and immunoreactivity were performed using Aida Analyzer v1.0 (Raytest) or Odyssey infrared imaging system (Lincoln).
TR-FRET LanthaScreen Cellular assay for LRRK2 pSer 935
LanthaScreen pSer 935 assays were performed essentially as described previously [11] . In brief, U2OS cells were transduced with 20 % BacMam LRRK2-GFP virus overnight. Cells were replated at 10 000 cells per well in 384 well plates. The cells were either left untreated or treated with 0.093, 1 or 10 μM LRRK2-IN1 inhibitor or in the presence of the indicated dilution series of calyculin A for 30 min. Cells were directly lysed in the presence of terbium-labelled pSer 935 antibody and, after 3 h incubation, TR-FRET ratios for terbium and GFP were read on a PerkinElmer EnVision Plate Reader.
Imunocytochemistry and proximity ligation assay
For immunocytochemistry, cells were grown on coverslips and washed with PBS and fixed with 4 % paraformaldehyde for 15 min, followed by two wash steps with PBS. After permeabilization for 5 min with PBST, a 30 min blocking step with 10 % goat serum (Dako cytomation) in PBS was performed. This was followed by a 2 h incubation with FLAG M2 and in-house anti-eGFP antibody in PBS. After three washes with PBS for 5 min, the cells were incubated for 1 h with secondary antibody (Alexa Fluor ® -conjugated antibody, 1:500 dilution, Molecular Probes) and washed three times for 5 min with PBS. The coverslips were mounted on a microscope slide with Mowiol (Sigma) supplemented with DAPI (Roche). Visualization was performed by confocal laser-scanning microscopy (Fluoview 1000, Olympus) using a 100 × lens.
PLAs were performed on eight-well CC2 chamber slides. Cells were fixed and permeabilized as in the immunocytochemistry experiments, then blocked with Duolink Blocking Solution for 30 min at 37
• C. Immediately after blocking, the cells were incubated with the indicated primary antibodies in the Duolink Antibody Diluent for 1 h at room temperature (20) (21) (22) (23) (24) • C). The cells were washed twice with Duolink Wash Buffer A for 5 min before the incubation of the PLUS and MINUS PLA probes. The cells were incubated with PLA probes for 1 h at 37
• C, followed by two washes with Wash Buffer A for 5 min. The cells were then incubated with pre-mixed Ligation-Ligase solution at 37
• C for 30 min. After two washes with Wash Buffer A for 2 min, the cells were incubated with pre-mixed Amplification-Polymerase solution for 60-90 min at 37
• C. Finally, the cells were washed twice with Duolink Wash Buffer B for 10 min, followed by 0.01 × Wash Buffer B for 1min. The slides were dried in the dark and mounted with Duolink II Mounting Medium. Images were quantified with the Duolink Image Tool Software (Version 1.0.1.2). Cellular phosphorylation sites reported by at least two independent studies (reviewed in [12] ) and investigated in the present study are depicted in blue, pathogenic LRRK2 mutations or risk factors are shown in red.
Figure S2 LRRK2 mutants show decreased metabolic labelling
Metabolic labelling of WT LRRK2 and mutations R1441C, Y1699C, K1906M, G2019S and G2385R.
32 P values were controlled for expression level and normalized to WT LRRK2 values. Results are consistent with reduced phosphorylation levels at Ser 910 and Ser 935 as previously reported (see text for more details). Representative blots are shown (with molecular mass indicated in kDa) and the histogram shows quantifications of four independent experiments, results are means + − S.E.M. **P < 0.01.
37
• C. Immediately after treatment, cells were fixed with 4 % paraformaldehyde for 20 min, permeabilized with 0.1 % Triton X-100 for 10 min and stained with primary anti-FLAG M2 antibody (2 ng/μl final concentration) and secondary anti-mouse Alexa Fluor ® 488-conjugated antibody (1:500 dilution, Invitrogen). Nuclei were stained with TO-PRO-3 iodide (Invitrogen). A total of 100-150 LRRK2-transfected cells per sample were counted over multiple fields on a 100 × objective for the presence of skein-like structures. Recombinant phosphatases were tested on generic substrates in the same conditions as those used to dephosphorylate LRRK2 in vitro (see Figure 1 of the main text). (A) The ability of different phosphatases to dephosphorylate PKA-phosphorylated MBP in vitro was tested. MBP was first labelled with radioactive phosphates by in vitro phosphorylation by PKA in the presence of [γ -32 P]ATP, then submitted to dephosphorylation (in the presence of 2 μM staurosporine to inhibit PKA) using the indicated panel of phosphatases as described in the Materials and methods section. Samples were analysed by SDS/PAGE and blotted to PVDF membranes as described in the Materials and methods section. Shown is the autoradiogram blot illustrating the incorporated 32 P levels. The graph in the lower panel of (A) shows the quantification of incorporated 32 P in MBP for each phosphatase relative to the control (non-dephosphorylated MBP). (B) The ability of different phosphatases to dephosphorylate pNPP (Sigma) in vitro was tested. Dephosphorylation was tested according to the manufacturer's instructions. Shown are quantifications of triplicate measures (means + − S.E.M.) relative to the maximum dephosphorylation given for alkaline phosphatase (for which values were set to zero,). CIP, calf intestinal alkaline phosphatase.
